**RSV Vaccines – Studies currently recruiting or in the process (19)**

*(Also includes a few ongoing studies (5) that are “active, not recruiting”)*

August 2, 2022

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| NCT04908683  “Evergreen” | Janssen | Phase 3 | 27,500 | 324 sites, worldwide | Adults 60+ |
| NCT05070546 | Janssen | Phase 3 | 1,100 | 27 sites, US & Europe | Adults 18-59 Healthy  Adults 18-59 High Risk  Adults 65+ |
| NCT05327816 | Janssen | Phase 1-2 | 1,600 | 29 sites, US & Europe | Adults 60+  Various formulations |
| NCT04909021 | Meissa Vaccines | Phase 1 | 63 | 12 sites, US only | Children 6-36 months  Nasal spray; live-virus |
| NCT04798001 | Meissa  Vaccines | Phase 1 | 130 | Johnson Co. Clin-Trials  Lenexa KS | Adults 18-55  Adults 56-70 |
| NCT04491877 | Sanofi | Phase 2 | 300 | 29 sites, US, Chile and Honduras | Children 6-18 months  Live-attenuated |
| NCT05242432 | Janssen | Phase 3 | 2,180 | 30 sites, Japan | Adults 20-59  Adults 60+ |
| NCT01893554 | NIAID | Phase 1 | 105 | 2 sites, US gov’t | Children 4-59 months  Started in 2013 |
| NCT03916185 | NIAID | Phase 1-2 | 160 | 18 sites, US only, academic | Children 6-24 months  Live-attenuated; since 2019 |
| NCT05238025 | Bavarian Nordic | Phase 3 | 20,000 | 79 sites, US only, commercial | Adults 60+  “Recombinant MVA” |
| NCT05301322 | Pfizer | Phase 3 | 2,230 | 32 sites, Australia | Adults 65+  “Prefusion F Subunit”  Given with flu vaccine |
| NCT05127434 | Moderna | Phase 2-3 | 34,000 | 70 sites, US only, commercial | Adults 60+  mRNA vaccine |
| NCT05281263 | Blue Lake Biotech | Phase 1 | 30 | Coastal Carolina Research Center | Adults 18-59  Adults 60-75 |
| NCT05330975  “RSVictory” | Moderna | Phase 3 | 1,350 | 34 sites, US only, commercial | Adults 50+ |
| NCT04424316 | Pfizer | Phase 3 | 10,000 | 468 sites, worldwide, **eight Ventavia sites** | Women <50 and their newborns |
| NCT04681833 | Advaccine  (Suzhou) | Phase 2 | 120 | CMAX Research  Australia | Adults 60-80 |
| NCT04919109 | Coda-genix | Phase 1 | 36 | Tekton Research (Codey Bell MD) | Children 6 months to 5 years |
| NCT04528719 | Moderna | Phase 1 | 651 | 21 sites, US only, commercial | Healthy adults  Seropositive kids, 1-5 |
| NCT05397223 | Moderna | Phase 1 | 300 | 8 sites, US only, commercial | Adults 18-75 (mRNA vaccines for flu, RSV, Covid and CMV) |
|  |  |  |  |  |  |
| *NCT05035212*  *Active, NR* | *Pfizer* | *Phase 3* | *32,232* | *262 sites, worldwide, commercial* | *Adults 60+* |
| *NCT03982199*  *Active, NR* | *Janssen* | *Phase 2* | *5,815* | *40 sites, US only, commercial* | *Adults 65+* |
| *NCT05071313*  *Active, NR* | *Janssen* | *Phase 3* | *777* | *19 sites, US only, commercial* | *Adults 65+*  *RSV vax + flu vax* |
| *NCT03502707*  *Active, NR* | *Janssen* | *Phase 1-2* | *669* | *Optimal Research, 6 US locations* | *Adults 60+* |
| *NCT04368728*  *Active, NR* | *Pfizer* | *Phase 2-3* | *46,949* | *164 sites, worldwide, mainly commercial* | *Ages 12 and up* |

Moderna and Eli Lilly are both developing CMV vaccines and Epstein-Barr vaccines